DFAS
Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

19
Volume
232,515.00
52W High
$62.65
52W Low
$48.66
50D MA
$59.95
Prev Close
$59.31
Loading...
Loading...
News
all
press releases
Exclusive: Opendoor CEO Reveals Company’s Own Mortgage Product Is In Beta Phase, Criticizes Fed On Interest Rates
OPEN’s CEO Kaz Nejatian said that truflation is a much better measure of inflation and no one who invests their own money looks at BLS data.
Stocktwits·4d ago
News Placeholder
More News
News Placeholder
RXT Stock Soared 275% Today – What’s The Connection With Palantir?
The company announced it would help businesses rapidly deploy Palantir’s Foundry and Artificial Intelligence Platform.
Stocktwits·7d ago
News Placeholder
Why Is Cineverse Stock Rising Despite Missing Q3 Revenue and Earnings Estimates?
The company said it expects $115 million to $120 million in revenue for fiscal year 2027, however analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai.
Stocktwits·7d ago
News Placeholder
B.Riley Stock Soars Nearly 40% - What’s Behind The Move?
Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline.
Stocktwits·1mo ago
News Placeholder
From Bitcoin Mining To AI: What’s Driving BitFarms’ Stock Jump Today?
BitFarms agreed to sell its 70 MW site in Paraguay to a crypto infrastructure fund for $30 million as part of its plans to fully exit LatAm.
Stocktwits·2mo ago
News Placeholder
One Stop Systems Stock Rises After Hours On Selling Bressner To Focus On Higher-Growth Segments
Hardware manufacturer OSS sold Bressner, which it acquired in October 2018, for $22.4 million to Hiper Euro GMBH on Tuesday.
Stocktwits·2mo ago
News Placeholder
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?
FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.
Stocktwits·2mo ago
News Placeholder
Why Did FuelCell Stock Rocket 35% Today?
The company reported fourth-quarter revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai.
Stocktwits·2mo ago
News Placeholder
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.
Stocktwits·4mo ago
News Placeholder
FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026
Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.
Stocktwits·4mo ago
<
1
2
...
>

Latest DFAS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.